- Home
- FBYD vs PROK Comparison
FBYD vs PROK Comparison
Compare FBYD & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBYD | PROK |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | 207 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.8M | 229.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBYD | PROK |
|---|---|---|
| Price | $11.28 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 108.9K | ★ 759.2K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $268.88 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $3.71 | $0.46 |
| 52 Week High | $29.02 | $7.13 |
Technical Indicators
Market Signals| Indicator | FBYD | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 61.15 | 45.75 |
| Support Level | $10.27 | $1.71 |
| Resistance Level | $13.05 | $2.58 |
| Average True Range (ATR) | 1.81 | 0.15 |
| MACD | 0.57 | -0.02 |
| Stochastic Oscillator | 53.39 | 44.30 |
Price Performance
Historical ComparisonAbout FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has four operating segments, Falcon's Creative Group, PDP, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.